Grail, Inc.
Grail, Inc. is listed today as Grail, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $325 M | Private placement after listing | $250 million to $1 billion | equity, options | SEC | |
| Nov 2019 | $388 M | No. 3 | $250 million to $1 billion | equity | SEC | |
| May 2018 | $300 M | No. 2 | $250 million to $1 billion | equity | SEC | |
| Feb 2017 | $1.2 B | No. 1 | $1 billion or more | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Grail, Inc., its revenue in fiscal 2025 came from these product and service lines: Screening revenue $138.60 million (94%), Development Services $8.57 million (6%).
Annual report (SEC XBRL) · Dec 2025
Grail, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).
SEC Form D · Nov 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2025
Products and services#
No products or services of Grail, Inc. are on record.
Investors#
No investor of Grail, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 59 investors.
Largest shareholders today
Institutions holding Grail, Inc. shares, as of Sep 30, 2026.
- Farallon Capital Management, L.L.C.$570 M9.05%
- Baker Bros. Advisors LP$564 M8.96%
- BlackRock, Inc.$537 M8.52%
- Primecap Management Co/ca/$311 M4.94%
- State Street Corp$282 M4.48%
- Vanguard Capital Management LLC$259 M4.10%
- Morgan Stanley$173 M2.75%
- Geode Capital Management, LLC$156 M2.48%
- Deep Track Capital, LP$155 M2.46%
- Bank Of America Corp /de/$106 M1.68%
- Sessa Capital IM, L.P.$105 M1.67%
- Dimensional Fund Advisors LP$105 M1.67%
- Goldman Sachs Group Inc$100 M1.59%
- Arbiter Partners Capital Management LLC$99 M1.57%
- Casdin Capital, LLC$95 M1.51%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aaron Freidin | Executive officer | Nov 2025 |
| Josh Ofman | Executive officer | Nov 2025 |
| Robert Ragusa | Executive officer | Nov 2025 |
| Hans Bishop | Executive officer | May 2020 |
| Jennifer T. Cook | Executive officer | May 2018 |
| William T. Rastetter | Executive officer | Nov 2017 |
| Jeffrey T. Huber | Executive officer | Apr 2017 |
| Gregory Summe | Director | Nov 2025 |
| Robert Ragusa | Director | Nov 2025 |
| Sarah Krevans | Director | Nov 2025 |
| Steve Mizell | Director | Nov 2025 |
| William Chase | Director | Nov 2025 |
| Catherine Friedman | Director | May 2020 |
| Hal Barron | Director | May 2020 |
| Hans Bishop | Director | May 2020 |
| Jeffrey Huber | Director | May 2020 |
| Kaye Foster | Director | May 2020 |
| Maykin Ho | Director | May 2020 |
| Min Cui | Director | May 2020 |
| Richard Klausner | Director | May 2020 |
| Robert Nelsen | Director | May 2020 |
| William Rastetter | Director | May 2020 |
| Brook T. Byers | Director | May 2018 |
| Catherine T. Friedman | Director | May 2018 |
| Jennifer T. Cook | Director | May 2018 |
| Kaye T. Foster | Director | May 2018 |
| Min T. Cui | Director | May 2018 |
| Richard T. Klausner | Director | May 2018 |
| Robert T. Nelsen | Director | May 2018 |
| William T. Rastetter | Director | May 2018 |
| Jeffrey T. Huber | Director | Jan 2018 |
| Jose T. Baselga | Director | Jan 2018 |
| Kaye T. Foster-Cheek | Director | Jan 2018 |
About
American biotechnology and pharmaceutical company.
Went public since 2023. Its SEC number is that of a company listed on a stock exchange.